Both in non-small cell lung cancer (NSCLC) and IPF, SPARC is predominantly localized in migrating fibroblasts within fibroblastic foci and drives pathological responses by promoting ECM synthesis and turnover (Tirelli et al., 2022). This evidence concerns the gene SPARC and non-small cell lung carcinoma.